During the 2013/14 influenza season in Canada, 631 of 654 hospitalisations for laboratory-confirmed influenza enrolled in sentinel hospitals were due to Influenza A. Of the 375 with known subtype, influenza A(H1N1) accounted for 357. Interim unmatched vaccine effectiveness adjusted for age and presence of one or more medical comorbidities was determined by testnegative case-control design to be 58.5% (90% confidence interval (CI): 43.9-69.3%) overall and 57.9% (90% CI: 37.7-71.5) for confirmed influenza A(H1N1).
In the context of the first influenza season in Canada since the 2009 influenza pandemic to be marked by the predominant circulation of A(H1N1)pdm09 virus, we provide a critical interim assessment of overall and age-stratified 2013/14 influenza vaccine effectiveness against laboratory-confirmed influenza-associated hospitalisation. We describe the clinical and epidemiological characteristics of severe cases of influenza, defined as those requiring intensive care unit (ICU) admission, mechanical ventilation or resulting in death, who were hospitalised up to 8 February 2014 in the hospitals of the Public Health Agency of Canada/ Canadian Institutes of Health Research (PCIRN) Serious Outcomes Surveillance (SOS) Network. The PCIRN SOS Network was established in 2009 to prospectively monitor annual seasonal influenza vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation in Canadian adults using a test-negative case-control design.
In Canada, annual influenza vaccine is recommended for all persons aged six months to 59 months or 65 years and older, and for persons of any age with medical comorbidities placing them at higher risk of severe influenza and its complications resulting in hospitalisation or death [1] . More than 98% of influenza vaccine provided to adults is intramuscular split-virus trivalent inactivated influenza vaccine (TIV).
Hospital-based surveillance
The PCIRN SOS Network comprises 40 adult academic and community hospitals in seven of the 10 Canadian provinces and three territories (New Brunswick, Nova Scotia, Quebec, Ontario, Manitoba, Alberta and British Columbia), accounting for ca 18,000 adult acute care hospital beds. For the 2013/14 season, beginning on 15 November 2013, trained SOS Network surveillance study staff (monitors) reviewed all daily admissions of people 16 years and older to medical and coronary ICU and medical wards (e.g. cardiology, respirology, family medicine, geriatric medicine, internal medicine) to identify eligible patients. Eligible patients were at least 16 years-old and admitted to participating hospitals with the following clinical presentations: pneumonia, acute exacerbation of chronic obstructive pulmonary disease or asthma, unexplained sepsis, any other respiratory infection or diagnosis, or any respiratory or influenza-like symptom (e.g. dypsnoea, cough, sore throat, myalgia, arthralgia, fever). One day per week, beginning when the local laboratory reported two or more positive influenza tests or when the local laboratory reported one or more positive influenza tests in two consecutive weeks, patients were screened who were admitted on that day with a triage temperature ≥37.5 °C associated with one of the following: acute coronary syndrome (e.g. myocardial infarction, unstable angina), any other cardiac diagnosis (e.g. atrial fibrillation, other arrhythmia, myocarditis), or stroke.
In hospitals associated with the Toronto Invasive Bacterial Diseases Network (TIBDN), influenza testing was performed seven days per week as routine clinical practice. A temperature cut-off of ≥37.5 °C was used in this subgroup of patients in order to attempt to minimise false-negative influenza PCR results associated with lag between influenza infection and related cardiac and stroke hospitalisations.
Nasopharyngeal swabs were collected from all eligible patients as part of routine clinical care or by the SOS Network monitor. The specimens were tested for influenza by reverse-transcriptase PCR (RT-PCR) or viral culture in the local hospital or public health laboratory according to routine local testing procedures. SOS Network monitors collected detailed demographic information, medical and surgical history, details of presenting illness, hospitalisation details including management and healthcare utilisation, discharge and 30-day post-discharge outcomes. The 2013/14 influenza immunisation history was collected from the patient or their caregiver and, if possible, verified with their immunisation provider or an immunisation registry. Patients were considered immunised if they reported receipt of a current-season influenza vaccine more than two weeks before onset of their symptoms. Only the subset of severe, life-threatening influenza requiring ICU admission, mechanical ventilation or causing death is described here in detail. 
Estimation of influenza vaccine effectiveness
All eligible patients hospitalised between 15 November 2013 and 8 February 2014 who underwent influenza testing and whose self-reported 2013/14 influenza immunisation status was available, were included in this interim analysis of vaccine effectiveness (VE). Hospitalised patients with a positive laboratory-test for influenza were defined as cases and those testing negative for influenza within seven days of onset of illness were defined as controls. Odds ratios (OR) for influenza vaccination among cases and controls were calculated and VE was estimated as (1−OR) x 100% by logistic regression adjusting for age and presence of one or more comorbidities. Overall adjusted VE and VE stratified by age (patients 65 years or older vs patients younger than 65 years) are presented. Rates of ICU admission among patients admitted to hospital with laboratory-confirmed influenza during the pandemic are readily available from many countries and range from a low of 10% in the United Kingdom and the Netherlands to highs of 25% to 30% in the United States (US) [4] [5] [6] [7] [8] . Fewer studies report rates of ICU admission among patients admitted with laboratoryconfirmed seasonal influenza, and rates vary widely by season and virus type/subtype [9] [10] [11] [12] . Over three influenza seasons (2005-08) in the US, 14% of hospitalised influenza cases required ICU admission while in the 2010/11 season, ICU admission was required for 25.5% of influenza A(H1N1), 13.5% of A(H3N2) and 15.9% of influenza B cases in the US and 27% of influenza A and 15% of influenza B hospitalisations in Australia [9] [10] [11] . In Spain, 24.4% of hospitalised patients with influenza in 2010/11 required admission to ICU [12] .
Interim estimates of influenza vaccine effectiveness
The majority of patients requiring admission to an ICU, requiring mechanical ventilation or who died in SOS Network hospitals during the 2013/14 season had underlying medical comorbidities known to increase the risk of influenza complications and making them eligible for free influenza vaccine. Despite this, vaccine coverage in this high-risk group was only 39%; of those with severe disease, only 33% overall and 21.7% of those under 65 years of age had been vaccinated.
Our interim adjusted point estimate for VE against laboratory-confirmed influenza-related hospitalisation of 58.5% (90% CI: 43.9-69.3) is similar to that reported in the United States (61%; 95% CI: 52-68) [13] but lower than that reported by the outpatient sentinel surveillance network for prevention of medically attended laboratory-confirmed influenza (74%; 95% CI: 58-83) [14] . This is not surprising given that the population captured by the outpatient sentinel surveillance network is dominated by healthy working -age adults with comparatively few underlying medical comorbidities while the PCIRN SOS Network assesses VE in a cohort of hospitalised patients who were older (median age: 65 vs 37 years) and much more likely to have underlying medical comorbidities (92 vs 22%) [14, 15] . Although lower than that observed for medically attended influenza in the community, effectiveness of the 2013/14 seasonal influenza vaccines in the prevention of serious, clinically important outcomes in adults of all ages was substantial, with reduction of influenza-associated hospitalisations of approximately 55-60%. As of 5 March 2014, the only other published study to report interim estimates of 2013/14 influenza VE against laboratory-confirmed hospitalisation is from Navarre, Spain, and reported lower overall and A(H1N1) specific VE [16] . However, potential differences in health systems, health seeking behaviour, number of cases and patterns of virus circulation (60% A(H3N2) and 40% A(H1N1) in the Navarre study) preclude a meaningful comparison with the present study.
Our findings are subject to at least two limitations. Firstly, as with other observational assessments of influenza vaccine effectiveness, the existence of bias and residual confounding cannot be excluded. We employed the test-negative case-control design, the currently preferred observational approach to assessing influenza vaccine effectiveness, to minimise misclassification and indication bias [17] . Secondly, while we are collecting data on numerous covariates in an attempt to adjust for potential confounders, these data were unavailable for the interim analysis. Consequently, the end-of-season, fully adjusted, VE estimates may be different. Although this has not been the experience of the Canadian outpatient sentinel surveillance network for the 2012/13 influenza season, the I-MOVE network in Europe reported important, but not statistically significant, differences between mid-season and end-ofseason VE estimates [14, 18] .
Our findings highlight that important public health benefits of influenza vaccination are lost to poor immunisation coverage rates in some at-risk populations. Targeted public health messaging is important to encourage adults of all ages with medical comorbidity to seek annual influenza vaccination. The 2013/14 season has been unique in that it is the first predominant influenza A(H1N1) season since the 2009 pandemic, allowing us to characterise potential changes in the epidemiology and clinical severity of influenza A(H1N1) pdm09 as it becomes a seasonal virus. These data are important to guide public health risk communication and inform immunisation, prevention, and treatment recommendations for the 2014/15 season, which are currently being developed by National Immunization Technical Advisory Groups (NITAGS) in many countries around the world, including the Canadian National Advisory Committee on Immunization (NACI).
While the demonstrated effectiveness of 58% against serious disease due to influenza is modest, it arguably represents a significant clinical, public health and health service/cost benefit, given the burden of severe disease resulting in hospitalisation and its downstream complications including ICU admission, pneumonia, disability and death. While our data for the current vaccine suggests prevention of almost 60% of influenza hospitalisations with vaccination in a well matched influenza A(H1N1)-dominated season affecting predominantly younger adults with comorbidity, the unchanged vaccine recommended by the World Health Organization for the 2014/15 season may have very different effectiveness (better or worse) in the coming season depending on circulating strains and vaccine match. While an anticipated VE of 58% against hospitalisation is reasonable given the effectiveness observed in 2013/14, ongoing surveillance and mid-season estimates during the coming season will be critical to ensure that the vaccine is performing as anticipated and to provide early signal of possible drift, should the VE be lower than anticipated. 
